MedTrace Logo

INcentives and ReMINDers to Improve Long-term Medication Adherence (INMIND)

NCT06949774 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 550

Last updated 2025-09-11

No results posted yet for this study

Summary

Low medication adherence when initiating antiretroviral treatment (ART) is a key barrier to HIV virologic suppression, resulting in avoidable cases of drug resistance, death, and viral transmission. Routinized pill-taking can lead to successful long-term ART adherence, and short-term behavioral economics-based supports are a novel way to overcome the limited success of existing routinization interventions. This study proposes to test this combined approach for promoting long-term ART adherence using a Stage III Sequential, Multiple Assignment, Randomized Trial (SMART) design in one of the largest HIV clinics in Uganda to identify the most cost-effective adaptive intervention that if found effective is generalizable to other settings and other chronic diseases.

Conditions

Interventions

BEHAVIORAL

Daily Text Messages

Participants will receive daily text message reminders to use their routine behavior to trigger medication adherence.

BEHAVIORAL

Incentivization based on timely ART adherence

Participants will be eligible to (draw a prize in monthly prize group) or get a monthly prize (monthly escalated group) if they take their medication within +/-one hour of the stated existing routine to which pill-taking is anchored on at least 80% of days for 3-months.

Sponsors & Collaborators

  • Arizona State University

    collaborator OTHER

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Mildmay Uganda Limited

    collaborator OTHER

  • RAND

    lead OTHER

Principal Investigators

  • Sebastian Linnemayr, Ph.D · RAND

  • Chad Stecher, Ph.D · Arizona State University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-02
Primary Completion
2028-12-31
Completion
2029-10-31

Countries

  • Uganda

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06949774 on ClinicalTrials.gov